vs
Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and STEM, INC. (STEM). Click either name above to swap in a different company.
Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $47.1M, roughly 1.6× STEM, INC.). Bioceres Crop Solutions Corp. runs the higher net margin — -9.6% vs -33.9%, a 24.3% gap on every dollar of revenue. On growth, STEM, INC. posted the faster year-over-year revenue change (-15.6% vs -16.8%). Over the past eight quarters, STEM, INC.'s revenue compounded faster (36.1% CAGR vs -8.4%).
Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.
BIOX vs STEM — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $77.6M | $47.1M |
| Net Profit | $-7.4M | $-16.0M |
| Gross Margin | 46.8% | 48.9% |
| Operating Margin | 9.3% | -17.7% |
| Net Margin | -9.6% | -33.9% |
| Revenue YoY | -16.8% | -15.6% |
| Net Profit YoY | -20.2% | 68.8% |
| EPS (diluted) | $-0.12 | $-4.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $47.1M | ||
| Q3 25 | $77.6M | $38.2M | ||
| Q2 25 | — | $38.4M | ||
| Q1 25 | $60.6M | $32.5M | ||
| Q4 24 | $98.8M | $55.8M | ||
| Q3 24 | $93.3M | $29.3M | ||
| Q2 24 | — | $34.0M | ||
| Q1 24 | $84.0M | $25.5M |
| Q4 25 | — | $-16.0M | ||
| Q3 25 | $-7.4M | $-23.8M | ||
| Q2 25 | — | $202.5M | ||
| Q1 25 | $-1.6M | $-25.0M | ||
| Q4 24 | $605.2K | $-51.1M | ||
| Q3 24 | $-6.2M | $-148.3M | ||
| Q2 24 | — | $-582.3M | ||
| Q1 24 | $9.8M | $-72.3M |
| Q4 25 | — | 48.9% | ||
| Q3 25 | 46.8% | 35.5% | ||
| Q2 25 | — | 33.4% | ||
| Q1 25 | 39.4% | 32.4% | ||
| Q4 24 | 42.0% | -4.4% | ||
| Q3 24 | 40.2% | 21.2% | ||
| Q2 24 | — | 27.6% | ||
| Q1 24 | 50.8% | -95.0% |
| Q4 25 | — | -17.7% | ||
| Q3 25 | 9.3% | -33.6% | ||
| Q2 25 | — | -34.8% | ||
| Q1 25 | 1.5% | -65.0% | ||
| Q4 24 | 14.5% | -84.4% | ||
| Q3 24 | 2.5% | -493.2% | ||
| Q2 24 | — | -1705.5% | ||
| Q1 24 | 15.7% | -267.0% |
| Q4 25 | — | -33.9% | ||
| Q3 25 | -9.6% | -62.2% | ||
| Q2 25 | — | 527.8% | ||
| Q1 25 | -2.6% | -76.9% | ||
| Q4 24 | 0.6% | -91.6% | ||
| Q3 24 | -6.6% | -506.3% | ||
| Q2 24 | — | -1712.6% | ||
| Q1 24 | 11.6% | -283.9% |
| Q4 25 | — | $-4.40 | ||
| Q3 25 | $-0.12 | $-2.84 | ||
| Q2 25 | — | $-1.79 | ||
| Q1 25 | $-0.02 | $-0.15 | ||
| Q4 24 | $0.00 | $-15.29 | ||
| Q3 24 | $-0.10 | $-18.24 | ||
| Q2 24 | — | $-71.81 | ||
| Q1 24 | $0.14 | $-0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $15.5M | $48.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $288.3M | $-249.4M |
| Total Assets | $734.9M | $308.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $48.9M | ||
| Q3 25 | $15.5M | $43.1M | ||
| Q2 25 | — | $40.8M | ||
| Q1 25 | $38.5M | $58.6M | ||
| Q4 24 | $29.2M | $56.3M | ||
| Q3 24 | $32.3M | $75.4M | ||
| Q2 24 | — | $89.6M | ||
| Q1 24 | $16.4M | $112.8M |
| Q4 25 | — | $-249.4M | ||
| Q3 25 | $288.3M | $-235.7M | ||
| Q2 25 | — | $-214.1M | ||
| Q1 25 | $345.0M | $-417.5M | ||
| Q4 24 | $346.3M | $-398.4M | ||
| Q3 24 | $346.0M | $-344.1M | ||
| Q2 24 | — | $-203.2M | ||
| Q1 24 | $348.5M | $371.6M |
| Q4 25 | — | $308.9M | ||
| Q3 25 | $734.9M | $362.6M | ||
| Q2 25 | — | $379.2M | ||
| Q1 25 | $798.2M | $405.1M | ||
| Q4 24 | $835.2M | $437.4M | ||
| Q3 24 | $827.3M | $537.8M | ||
| Q2 24 | — | $691.5M | ||
| Q1 24 | $836.1M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.4M | $8.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $8.2M | ||
| Q3 25 | $14.4M | $11.4M | ||
| Q2 25 | — | $-21.3M | ||
| Q1 25 | $23.3M | $8.5M | ||
| Q4 24 | $-5.4M | $-14.7M | ||
| Q3 24 | $5.2M | $-9.4M | ||
| Q2 24 | — | $-11.9M | ||
| Q1 24 | $-17.4M | $-621.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | -8.85× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.78× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
